Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cejinzan is a traditional Chinese medicine (TCM) formulation developed as a topical patch for the treatment of recurrent aphthous ulcers (RAU). Developed by the Shandong Institute of Biological Medicine, it is specifically investigated for mild RAU using TCM syndrome stratification to guide therapy. The patch is designed to be applied directly to the oral mucosa, where it likely exerts anti-inflammatory and mucosal-protective effects to accelerate ulcer healing and provide symptomatic relief. As a botanical-based therapy, its mechanism involves a complex interplay of multiple active constituents typical of herbal preparations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cejinzan.